Trial
NCT01382706
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI); GlaxoSmithKline
Condition
Recurrent Bladder Cancer
Intervention
docetaxel
Why stopped
Trial not progressing toward scientific goals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-09